Leukaemia research leads to hope for brain cancer patients
Research initiated by head of the Leukaemia Foundation Research Unit at the QIMR Berghofer Medical Research Institute, Professor Andrew Boyd, and collaborators has not only led to clinical trials for blood cancer patients, it’s showing promise for other cancers too.
Professor Boyd developed an antibody that targets a cancer protein on the surface of tumour cells, with the recent successful completion of a Phase I study involving leukaemia patients.
An upcoming clinical trial for brain cancer patients will be the first test of the treatment against solid tumours. The trial will be conducted by QIMR Berghofer – led by Dr Brett Stringer and Dr Bryan Day – and the Ludwig Institute for Cancer Research.
You can read more about the announcement on the QIMR Berghofer website.
The Leukaemia Foundation of Queensland is a strong supporter of collaborative research and is proud to have funded the work of Professor Boyd and Dr Stringer over the past decade.